News
An Acosta Group study finds that 76% of those who discontinued GLP-1s are eating the same amount or less and many report ...
As GLP-1s quiet the constant hum of hunger, are they a permanent pharmaceutical crutch, or can they create space to let us ...
Zacks Small Cap Research on MSN2h
MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%…MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Positive Phase 1 MAD Data for DA-1726 On April 15, 2025, MetaVia Inc. (NASDAQ:MTVA) announced positive results from the Phase 1 Part 2 multiple ...
Skye Bioscience currently trades essentially at cash value, meaning investors who buy in today get a weight loss drug ...
Zacks Investment Research on MSN5h
Eli Lilly Stock Down 8.2% in a Month: Should You Buy the Dip?Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...
Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...
The rapid increase in the use of glucagon-like peptide-1 receptor agonists for weight loss, diabetes management and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback